SCHEMBL16084484

SCHEMBL16084484

CC(C)(C)CCC(=O)Nc1nc2ccc(Cl)nc2n1C1CCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.37
CYP11B1 P15538 3/20 0.37
RORC P51449 2/20 0.36
P2RX7 Q99572 1/20 0.34
MAPK8 P45983 2/20 0.33
MAPK9 P45984 2/20 0.33
MAPK10 P53779 2/20 0.33
MAPK14 Q16539 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
OGFRL1 Q5TC84 1/20 0.33
RPS6KA3 P51812 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HIF1A Q16665 1/20 0.33
ALK Q9UM73 3/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084497 0.90 CYP11B2 (0.35) CYP11B2CYP11B1RORCP2RX7MAPK8
SCHEMBL16084213 0.89 CYP11B2 (0.38) CYP11B2CYP11B1P2RX7OPRM1OPRD1
SCHEMBL17481433 0.88 RORC (0.38) RORCMAPK8MAPK9MAPK10MAPK14
SCHEMBL16084174 0.87 CYP11B1 (0.35) CYP11B2CYP11B1RORCP2RX7OPRM1
SCHEMBL16084524 0.87 EGFR (0.37) RORCEGFR
SCHEMBL16084214 0.86 ALDH1A1 (0.45) RORCP2RX7ALDH1A1HPGD
SCHEMBL19276069 0.86 CYP11B2 (0.38) CYP11B2CYP11B1P2RX7OPRM1OPRD1
SCHEMBL19276194 0.86 CYP11B2 (0.36) CYP11B2CYP11B1P2RX7MAPK8MAPK9
SCHEMBL16084479 0.86 CYP11B2 (0.38) CYP11B2CYP11B1P2RX7MAPK8MAPK9
SCHEMBL20624463 0.85 CYP11B1 (0.37) CYP11B2CYP11B1P2RX7MAPK9OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11724990-B2 Kv7 channel activators compositions and methods of use BIOHAVEN THERAPEUTICS LTD. (VG) 2023-08-15 US disclosed
US-11724990-B2 Kv7 channel activators compositions and methods of use BIOHAVEN THERAPEUTICS LTD. (VG) 2023-08-15 US disclosed
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2023-01-05 US disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
EP-2970277-B1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2021-07-28 EP disclosed
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 US disclosed
US-10851067-B2 Kv7 channel activators compositions and methods of use KNOPP BIOSCIENCES LLC (US) 2020-12-01 US disclosed
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2019-09-19 US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-9650376-B2 Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators KNOPP BIOSCIENCES LLC (US) 2017-05-16 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2016-02-04 US disclosed
WO-2014145852-A2 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 CYP11B2 3344/4885CYP11B1 3429/4885RORC 2225/4885
US-11724990-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 CYP11B2 3344/4885CYP11B1 3429/4885RORC 2225/4885
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 CYP11B2 3344/4885CYP11B1 3429/4885RORC 2225/4885
US-20160031875-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 CYP11B2 1933/4885CYP11B1 1968/4885RORC 2198/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 CYP11B2 2067/4885CYP11B1 2093/4885RORC 2173/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 CYP11B2 1933/4885CYP11B1 1968/4885RORC 2198/4885
US-10851067-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 CYP11B2 3344/4885CYP11B1 3429/4885RORC 2225/4885
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 CYP11B2 3344/4885CYP11B1 3429/4885RORC 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.